Clostridium difficile infection: new developments in epidemiology and pathogenesis
The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
Abstract
Clostridium difficile is now considered to be one of the most important causes of health care-associated infections. C. difficile infections are also emerging in the community and in animals used for food, and are no longer viewed simply as unpleasant complications that follow antibiotic therapy. Since 2001, the prevalence and severity of C. difficile infection has increased significantly, which has led to increased research interest and the discovery of new virulence factors, and has expanded and focused the development of new treatment and prevention regimens. This Review summarizes the recent epidemiological changes in C. difficile infection, our current knowledge of C. difficile virulence factors and the clinical outcomes of C. difficile infection.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, studies have demonstrated that patients suffering from recurrent CDI are deficient in phyla of bacteria normally dominant in the colon6,45 (Figure 1).”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [45]
Citations
Cites
Dethlefsen, L., Huse, S., Sogin, M. L., & Relman, D. A. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060280 · Cited by 2,361 · cited 1×
“It is becoming evident from 16S ribosomal RNA sequencing that disruption of the gut microbiota following antibiotic treatment is much greater than was previously realize”
BackgroundAn Epidemic, Toxin Gene–Variant Strain of Clostridium difficile
McDonald, L. C., Killgore, G. E., Thompson, A., Owens, R. C., Kazakova, S. V., Sambol, S. P., Johnson, S., & Gerding, D. N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051590 · Cited by 2,006
Loo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., Bourgault, A.-M., Nguyen, T., Frenette, C., Kelly, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051639 · Cited by 1,946
Interventions to improve antibiotic prescribing practices for hospital inpatients
Davey, P., Brown, E., Charani, E., Fenelon, L., Gould, I. M., Holmes, A., Ramsay, C. R., Wiffen, P. J., & Wilcox, M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003543.pub3 · Cited by 1,864
Nosocomial Acquisition of Clostridium difficile Infection
McFarland, L. V., Mulligan, M. E., Kwok, R. Y. Y., & Stamm, W. E. (1989) · New England Journal of Medicine · doi:10.1056/nejm198901263200402 · Cited by 1,326
Zar, F. A., Bakkanagari, S. R., Moorthi, K. M. L. S. T., & Davis, M. B. (2007) · Clinical Infectious Diseases · doi:10.1086/519265 · Cited by 1,252
Pepin, J. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041104 · Cited by 1,128
Glucosylation of Rho proteins by Clostridium difficile toxin B
Just, I., Selzer, J., Wilm, M., Eichel-Streiber, C. V., Mann, M., & Aktories, K. (1995) · Nature · doi:10.1038/375500a0 · Cited by 1,032
Decreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile–Associated Diarrhea
Chang, J. Y., Antonopoulos, D. A., Kalra, A., Tonelli, A., Khalife, W. T., Schmidt, T. M., & Young, V. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/525047 · Cited by 1,010
Pepin, J., Saheb, N., Coulombe, M.-A., Alary, M.-E., Corriveau, M.-P., Authier, S., Leblanc, M., Rivard, G., Bettez, M., Primeau, V., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/496986 · Cited by 995
Research works printed but not linked: 5
- Summary points on quarterly (October to December. 2008) and financial year (2007/08) acute Trust Clostridium difficile data. Key points: analyses of quarterly mandatory Clostridium difficile surveillance data. Health Protection Agency [online] , (2008).
- Thompson, A. et al. in Ninth Biennial Congress of the Anaerobe Society of Americas. PII-14 (Long Beach, California, 2008).
- Angulo, F. et al. in Second International Clostridium difficile Symposium. P5 (Maribor, Slovenia, 2007).
- Louie, T. et al. in The 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. K-425a (Chicago, Illinois, 2007).
- Merrigan, M. M., Gerding, D. N. & Vedantam, G. in Eighth Biennial Conference of the Anaerobe Society of America. PI-12 (Boise, Idaho, 2006).
Cited by
Items 501–600 of 999
Detecting and Treating Clostridium Difficile Infections in Patients with Inflammatory Bowel Disease
Ananthakrishnan, A. N. (2012) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2012.01.003 · Cited by 39
Bezlotoxumab: A Novel Agent for the Prevention of Recurrent Clostridium difficile Infection
Kufel, W. D., Devanathan, A. S., Marx, A. H., Weber, D. J., & Daniels, L. M. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1990 · Cited by 37
The role of zinc and nutritional immunity inClostridium difficileinfection
Zackular, J. P., & Skaar, E. P. (2018) · Gut Microbes · doi:10.1080/19490976.2018.1448354 · Cited by 43
Berger, F. K., Rasheed, S., Araj, G. F., Mahfouz, R. A., Rimmani, H. H., Karaoui, W. R., Sharara, A. I., Dbaibo, G. S., Becker, S. L., von Müller, L., et al. (2018) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2018.01.004 · Cited by 39
Balassiano, I. T., dos Santos-Filho, J., de Oliveira, M. P. B., Ramos, M. C., Japiassú, A. M., dos Reis, A. M., Brazier, J. S., Ferreira, E. D. O., & Domingues, R. M. C. P. (2010) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2010.07.017 · Cited by 36
“017 branous colitis, toxic megacolon, bowel perforation, sepsis, shock, and death (Rupnik et al., 2009).”
BackgroundInfluentialJohnston, P. F., Gerding, D. N., & Knight, K. L. (2013) · Infection and Immunity · doi:10.1128/iai.01273-13 · Cited by 42
“Standard antibiotic treatment for CDI is often ineffective, and no vaccines are available (1).”
BackgroundInfluentialPresence of Clostridium difficile in poultry and poultry meat in Egypt
Abdel‐Glil, M. Y., Thomas, P., Schmoock, G., El-Azm, K. I. A., Wieler, L. H., Neubauer, H., & Seyboldt, C. (2018) · Anaerobe · doi:10.1016/j.anaerobe.2018.03.009 · Cited by 36
“difficile (CDI) is affecting mostly elderly individuals receiving antibiotics under hospital settings [1].”
BackgroundKubota, H., Sakai, T., Gawad, A., Makino, H., Akiyama, T., Ishikawa, E., & Oishi, K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111684 · Cited by 35
“Clostridium difficile is the most common cause of healthcareassociated infectious diarrhea [1].”
BackgroundLi, S., Shi, L., Yang, Z., & Feng, H. (2012) · Pathogens and Disease · doi:10.1111/2049-632x.12016 · Cited by 35
“TcdB, in particular, is critical for virulence and is found in all clinically isolated pathogenic strains (Lyras et al., 2009; Rupnik et al., 2009; Kuehne et al., 2010).”
Taori, S. K., Hall, V., & Poxton, I. R. (2009) · Journal of Medical Microbiology · doi:10.1099/jmm.0.014829-0 · Cited by 35
Tsutsumi, L. S., Owusu, Y., Hurdle, J. G., & Sun, D. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026613666131113154753 · Cited by 42
“Also, since 2000, there has been an increase in the number of outbreaks of CDI in hospitals following the emergence of seemingly more virulent strains that are more refractory to treatments [20].”
InfluentialAnosova, N. G., Cole, L. E., Li, L., Zhang, J., Brown, A. M., Mundle, S. T., Zhang, J., Ray, S., Ma, F., Garrone, P., et al. (2015) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00763-14 · Cited by 35
“7 cases per 100,000 person-years, of which 35% were not associated with antibiotics (1).”
BackgroundDetection of Clostridium difficile toxins A, B and binary toxin with slow off-rate modified aptamers
Ochsner, U. A., Katilius, E., & Janjić, N. (2013) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2013.03.029 · Cited by 35
“, fluoroquinolones) are hallmarks of these strains (Carroll and Bartlett 2011; Freeman et al., 2010; Lanis et al., 2010; Rupnik et al., 2009; Stabler et al., 2009; Warny et al., 2005).”
BackgroundSpigaglia, P., Barketi-Klai, A., Collignon, A., Mastrantonio, P., Barbanti, F., Rupnik, M., Janežič, S., & Kansau, I. (2013) · Journal of Medical Microbiology · doi:10.1099/jmm.0.056556-0 · Cited by 43
“Antibiotic exposure, advanced age and hospitalization are the major factors associated with C. difficile infection (CDI) (Kelly et al., 1994; Rupnik et al., 2009).”
BackgroundBaliban, S. M., Michael, A., Shammassian, B. H., Mudakha, S., Khan, A. S., Cocklin, S., Zentner, I., Latimer, B. P., Bouillaut, L., Hunter, M., et al. (2014) · Infection and Immunity · doi:10.1128/iai.01950-14 · Cited by 36
“Clostridium difficile infection (CDI) is the leading cause of nosocomial antibiotic-associated diarrhea in developed countries, with 500,000 new infections and 20,000 deaths occurring annually in the United States alone (1).”
BackgroundMraheil, M. A., Billion, A., Kuenne, C. T., Pischimarov, J., Kreikemeyer, B., Engelmann, S., Hartke, A., Giárd, J.-C., Rupnik, M., Vorwerk, S., et al. (2010) · Microbial Biotechnology · doi:10.1111/j.1751-7915.2010.00171.x · Cited by 38
“Clostridium difficile is currently one of the increasingly important nosocomial pathogens, but also rising are the numbers of human community-associated infections and animal infections (Rupnik et al., 2009).”
BackgroundPaiva, A. M. O., Friggen, A. H., Hossein-Javaheri, S., & Smits, W. K. (2016) · ACS Synthetic Biology · doi:10.1021/acssynbio.6b00104 · Cited by 37
Warn, P. A., Thommes, P. A., Sattar, A., Corbett, D. F., Flattery, A. M., Zhang, Z., Black, T. A., Hernandez, L. D., & Therien, A. G. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00974-16 · Cited by 37
“Generally, OTUs clustered in four distinct patterns that included (1) organisms that were present at a high level in naive animals, decreased in abundance with cefoperazone/clindamycin treatment, and did not return by day 28; (2) organisms that were absent in naive animals, began to colonize the gut on day 5, and pers…”
BackgroundSurvival and prevalence of Clostridium difficile in manure compost derived from pigs
Usui, M., Kawakura, M., Yoshizawa, N., San, L. L., Nakajima, C., Suzuki, Y., & Tamura, Y. (2016) · Anaerobe · doi:10.1016/j.anaerobe.2016.11.004 · Cited by 40
“difficile infection (CDI) has become more common and more severe in developed countries [1].”
BackgroundHawkins, K. G., Casolaro, T. C., Brown, J. A., Edwards, D. A., & Wikswo, J. P. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1870 · Cited by 39
“…for diseases caused by dysbiosis (i.e., a change in microbial composition or function that has an adverse impact on the host-microbiome relationship), as can be induced by antibiotics during a Clostridium difficile infection, 33 or as can occur following an ileocecal resection and antibiotics.”
BackgroundBuckley, A. M., Moura, I. B., Arai, N., Spittal, W. D., Clark, E., Nishida, Y., Harris, H. C., Bentley, K., Davis, G. L., Wang, D., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.670935 · Cited by 35
Antibiotic Resistance and Biofilm Production Capacity in Clostridioides difficile
Rahmoun, L. A., Azrad, M., & Peretz, A. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.683464 · Cited by 35
Single Domain Antibody application in bacterial infection diagnosis and neutralization
Qin, Q., Liu, H., He, W., Guo, Y., Zhang, J., She, J., Zheng, F., Zhang, S., Muyldermans, S., & Wen, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1014377 · Cited by 35
McDermott, A. J., Frank, C. R., Falkowski, N. R., McDonald, R. A., Young, V. B., & Huffnagle, G. B. (2014) · Gut Microbes · doi:10.4161/gmic.29964 · Cited by 36
Obuch-Woszczatyński, P., Lachowicz, D., Schneider, A., Mól, A., Pawłowska, J., Ożdżeńska-Milke, E., Pruszczyk, P., Wultańska, D., Młynarczyk, G., Harmanus, C., et al. (2014) · Anaerobe · doi:10.1016/j.anaerobe.2014.04.007 · Cited by 35
Critical Roles of Clostridium difficile Toxin B Enzymatic Activities in Pathogenesis
Li, S., Shi, L., Yang, Z., Zhang, Y., Pérez‐Cordón, G., Huang, T., Ramsey, J. P., Oezguen, N., Savidge, T., & Feng, H. (2014) · Infection and Immunity · doi:10.1128/iai.02316-14 · Cited by 35
Qin, J., Dai, Y., Ma, X., Wang, Y., Gao, Q., Lu, H., Li, T., Meng, H., Liu, Q., & Li, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-09878-8 · Cited by 35
Brouwer, M. S. M., Roberts, A. P., Mullany, P., & Allan, E. (2012) · Mobile Genetic Elements · doi:10.4161/mge.19297 · Cited by 34
“It produces toxins during infection that affect gut epithelia leading to a range of diseases from mild, self-limiting diarrhea to the often fatal pseudomembranous colitis.(1) C.”
S-layers: The Proteinaceous Multifunctional Armors of Gram-Positive Pathogens
Ravi, J., & Fioravanti, A. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.663468 · Cited by 37
Asensio, Á., Bella, S. D., Vecchio, A. L., Grau, S., Hart, W. M., Isidoro, B., Scotto, R., Petrosillo, N., Watt, M., & Nazir, J. (2015) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2015.05.013 · Cited by 42
“elderly, chronically ill, and immunocompromised patients.(2,3) However, CDI is becoming an increasingly common cause of community-acquired diarrhoea in low-risk populations, such as children, healthy adults, and pregnant women.”
BackgroundInduction of cytokines in a macrophage cell line by proteins ofClostridium difficile
Vohra, P., & Poxton, I. R. (2012) · FEMS Immunology & Medical Microbiology · doi:10.1111/j.1574-695x.2012.00952.x · Cited by 39
“difficile is the most common cause of hospital-acquired diarrhoea today (Rupnik et al., 2009), it is not limited to the hospital environment; community-acquired CDI and asymptomatic carriage are also prevalent (Limbago et al.”
BackgroundSurface layer proteins isolated from Clostridium difficile induce clearance responses in macrophages
Collins, L. E., Lynch, M., Marszalowska, I., Kristek, M., Rochfort, K. D., O’Connell, M. J., Windle, H. J., Kelleher, D. P., & Loscher, C. E. (2014) · Microbes and Infection · doi:10.1016/j.micinf.2014.02.001 · Cited by 39
“With the aid of flagella, proteases and other surface proteins, they can penetrate deep into the mucous layer of the intestine [3].”
BackgroundBalassiano, I. T., dos Santos-Filho, J., Vital-Brazil, J. M., Nouér, S. A., Souza, C. R. C., Brazier, J. S., Ferreira, E. D. O., & Domingues, R. M. C. P. (2010) · Antonie van Leeuwenhoek · doi:10.1007/s10482-010-9483-8 · Cited by 34
“In addition, this strain also produces a binary toxin (CDT), whose role in disease is still not well understood (Barbut et al. 2005), shows alterations in SlpA (surface layer protein A) associated with increased adherence to human intestinal epithelial cells ( Rupnik et al. 2009 ), presents more motility and resistanc…”
BackgroundUsui, M., Nanbu, Y., Oka, K., Takahashi, M., Inamatsu, T., Asai, T., Kamiya, S., & Tamura, Y. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00513 · Cited by 34
“ORIGINAL RESEARCH ARTICLE published: 08 October 2014 doi: 10.3389/fmicb.2014.00513 Genetic relatedness between Japanese and European isolates of Clostridium difficile originating from piglets and their risk associated with human health”
BackgroundInfluentialLofgren, E., Moehring, R. W., Anderson, D. J., Weber, D. J., & Fefferman, N. H. (2013) · Infection Control and Hospital Epidemiology · doi:10.1086/674394 · Cited by 37
Impact ofClostridium difficileon inflammatory bowel disease
Ananthakrishnan, A. N., & Binion, D. G. (2010) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.10.55 · Cited by 36
Pros, cons and future of antibiotics
Weledji, E. P., Weledji, E. K., Assob, J. C. N., & Nsagha, D. S. (2017) · New Horizons in Translational Medicine · doi:10.1016/j.nhtm.2017.08.001 · Cited by 36
“The serious complication of pseudomembranous colitis, is caused by the anaerobic bacterium, Clostridium difficile, which can multiply when the normal colonic flora is suppressed and is relatively insusceptible to many commonly used antibiotics but metronidazole or vancomycin [36, 37].”
BackgroundOka, K., Osaki, T., Hanawa, T., Kurata, S., Sugiyama, E., Takahashi, M., Tanaka, M., Taguchi, H., & Kamiya, S. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01264 · Cited by 36
“difficile infection (CDI) is not well understood (Drudy et al., 2007; Lyras et al., 2009; Rupnik et al., 2009; Kuehne et al., 2010).”
BackgroundAppaneal, H. J., Caffrey, A. R., Beganovic, M., Avramovic, S., & LaPlante, K. L. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy175 · Cited by 35
Seugendo, M., Janssen, I., Lang, V., Hasibuan, I., Bohne, W., Cooper, P., Daniel, R., Gunka, K., Kusumawati, R. L., Mshana, S. E., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01843 · Cited by 34
“It is widely known that advanced age and its consecutive comorbidities is one of the most important risk factors for CDI (Rupnik et al., 2009; Bauer et al., 2011; Leffler and Lamont, 2015).”
BackgroundInfluentialMolecular epidemiology of predominant and emerging Clostridioides difficile ribotypes
Martínez-Meléndez, A., Morfín‐Otero, R., Villarreal-Treviño, L., Baines, S. D., Camacho-Ortíz, A., & Garza‐González, E. (2020) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2020.105974 · Cited by 34
Ternan, N. G., Jain, S., Srivastava, M., & McMullan, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042410 · Cited by 41
“causes of health care-associated infections [1] and is said to be the”
BackgroundThe Contribution of Bacteriophages to the Biology and Virulence of Pathogenic Clostridia
Fortier, L. (2017) · Advances in applied microbiology · doi:10.1016/bs.aambs.2017.05.002 · Cited by 37
Maharshak, N., Barzilay, I., Zinger, H., Hod, K., & Dotan, I. (2018) · Medicine · doi:10.1097/md.0000000000009772 · Cited by 44
Modulation of Intestinal Paracellular Transport by Bacterial Pathogens
Roxas, J. L., & Viswanathan, V. K. (2018) · Comprehensive physiology · doi:10.1002/cphy.c170034 · Cited by 36
Wang, X., Cai, L., Yu, R., Huang, W., & Zong, Z. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111735 · Cited by 33
“Clostridium difficile, a Gram-positive spore-forming anaerobic bacterium, is the leading cause of nosocomial diarrhea in industrialized countries [1,2].”
BackgroundClostridium difficile–associated infection: a disease of varying severity
Jawa, R. S., & Mercer, D. (2012) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2012.05.025 · Cited by 38
Ting, L. S. L., Præstgaard, J., Grunenberg, N. A., Yang, J. C., Leeds, J. A., & Pertel, P. E. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00867-12 · Cited by 33
“Increasingly, however, the disease is recognized in individuals with no recent antibiotic exposure and in previously low-risk groups, such as children, pregnant women, and those with irritable bowel syndrome (17).”
BackgroundEtienne‐Mesmin, L., Chassaing, B., Adekunle, O., Mattei, L. M., Bushman, F. D., & Gewirtz, A. T. (2017) · Gut · doi:10.1136/gutjnl-2016-313510 · Cited by 36
“difficile) is a leading cause of nosocomial disease [1, 2, 3].”
BackgroundNeumann‐Schaal, M., Metzendorf, N. G., Troitzsch, D., Nuss, A. M., Hofmann, J. D., Beckstette, M., Dersch, P., Otto, A., & Sievers, S. (2018) · Anaerobe · doi:10.1016/j.anaerobe.2018.05.018 · Cited by 32
Li, X., Yang, B., Shi, C., Wang, H., Yu, R., Li, Q., & Liu, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.859975 · Cited by 44
Bruins, M. J., Verbeek, E., Wallinga, J. A., van Coppenraet, L. E. S. B., Kuijper, E. J., & Bloembergen, P. (2012) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-012-1658-y · Cited by 33
“difficile), is a life-threatening disease that in the last decade has become more prevalent, not only as a healthcare-associated, but also as a communityacquired infection [10, 24].”
BackgroundEpidemiology of Clostridium difficile: a hospital-based descriptive study in Argentina and Mexico
Lopardo, G. D., Morfín‐Otero, R., Moran-Vazquez, I. I., Noriega, F. R., Zambrano, B., Luxemburger, C., Foglia, G., & Rivas, E. (2014) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2014.07.004 · Cited by 33
Advances in the Microbiome: Applications to Clostridium difficile Infection
Culligan, E. P., & Sleator, R. D. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5090083 · Cited by 39
“In addition to hospitalization, the most significant predisposing factors for CDI include advanced age (>65 years) and antibiotic therapy (disrupts the normal gut microbiota) [32].”
BackgroundNycz, B. T., Dominguez, S. R., Friedman, D., Hilden, J. M., Ir, D., Robertson, C. E., & Frank, D. N. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191232 · Cited by 39
Srikhanta, Y. N., Hutton, M. L., Awad, M. M., Drinkwater, N., Singleton, J., Day, S. L., Cunningham, B. A., McGowan, S., & Lyras, D. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0519-1 · Cited by 33
Curry, S. R. (2010) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2010.04.001 · Cited by 47
Cornely, O. A. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12012 · Cited by 32
“difficile with reduced susceptibility to metronidazole [12], treatment failure has not been directly associated with drug resistance [13].”
Argamany, J. R., Aitken, S. L., Lee, G. C., Boyd, N. K., & Reveles, K. R. (2015) · American Journal of Infection Control · doi:10.1016/j.ajic.2014.11.018 · Cited by 32
Immunization strategies forClostridium difficileinfections
Rebeaud, F., & Bachmann, M. F. (2012) · Expert Review of Vaccines · doi:10.1586/erv.12.18 · Cited by 33
Marreddy, R. K. R., Wu, X., Sapkota, M., Prior, A. M., Jones, J. A., Sun, D., Hevener, K. E., & Hurdle, J. G. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.8b00205 · Cited by 35
Dual role of the colonization factor CD2831 in Clostridium difficile pathogenesis
Arato, V., Gasperini, G., Giusti, F., Ferlenghi, I., Scarselli, M., & Leuzzi, R. (2019) · Scientific Reports · doi:10.1038/s41598-019-42000-8 · Cited by 35
Zhu, Z., Schnell, L., Müller, B., Müller, M., Papatheodorou, P., & Barth, H. (2019) · Stem Cells International · doi:10.1155/2019/4149762 · Cited by 32
(2019) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-019-02959-1 · Cited by 35
de Graaf, H., Pai, S., Burns, D. A., Karas, J. A., Enoch, D., & Faust, S. N. (2015) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-015-2367-0 · Cited by 32
Kim, S. H., Jeung, W., Choi, I.-D., Jeong, J.-W., Lee, D. E., Huh, C., Kim, G.-B., Hong, S. S., Shim, J.-J., Lee, J. L., et al. (2016) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.1512.12002 · Cited by 37
“An important example of this problem is the prevalence of antibioticassociated diarrhea [37, 42, 53, 56].”
BackgroundEffects of Surotomycin on Clostridium difficile Viability and Toxin Production In Vitro
Bouillaut, L., McBride, S. M., Sorg, J. A., Schmidt, D., Suárez, J. M., Tzipori, S. R., Mascio, C. T. M., Chesnel, L., & Sonenshein, A. L. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00275-15 · Cited by 32
“In addition, many cases of CDI in the United States are now linked to a family of more-virulent strains (NAP1/ BI/027) that emerged first in the United Kingdom and then in Canada (8, 9).”
BackgroundC. difficile ribotype 027 or 176?
Krůtová, M., Matějková, J., & Nyč, O. (2014) · Folia Microbiologica · doi:10.1007/s12223-014-0323-5 · Cited by 31
“Early identification of toxigenic strains is necessary for taking measures against the spread of infection and the correct timing of adequate therapy (Rupnik et al. 2009).”
Rotramel, A. R., Poritz, L. S., Messaris, E., Berg, A. S., & Stewart, D. B. (2012) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-012-2037-9 · Cited by 31
Gerding, D. N., Hecht, D. W., Louie, T., Nord, C. E., Talbot, G. H., Cornely, O. A., Buitrago, M. I., Best, E. L., Sambol, S. P., Osmolski, J. R., et al. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv300 · Cited by 31
Moradigaravand, D., Gouliouris, T., Ludden, C., Reuter, S., Jamrozy, D. M., Blane, B., Naydenova, P., Judge, K., Aliyu, S. H., Hadjirin, N. F., et al. (2018) · Microbial Genomics · doi:10.1099/mgen.0.000162 · Cited by 36
Wultańska, D., Piotrowski, M., & Pituch, H. M. (2020) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-03857-0 · Cited by 35
Oberkampf, M., Hamiot, A., Altamirano-Silva, P., Bellés-Sancho, P., Tremblay, Y. D. N., DiBenedetto, N., Seifert, R., Soutourina, O. A., Bry, L., Dupuy, B., et al. (2022) · Science Signaling · doi:10.1126/scisignal.abn8171 · Cited by 35
Arruda, P., Madson, D., Ramirez, A., Rowe, E., Lizer, J. T., & Songer, J. G. (2013) · Anaerobe · doi:10.1016/j.anaerobe.2013.04.010 · Cited by 40
Draft Genome Sequence of the Nontoxigenic Clostridium difficile Strain CD37
Brouwer, M. S. M., Allan, E., Mullany, P. P., & Roberts, A. P. (2012) · Journal of Bacteriology · doi:10.1128/jb.00122-12 · Cited by 36
“The main virulence factors are the toxins A and B and the less-well-characterized binary toxin (18).”
BackgroundA detection dog to identify patients with Clostridium difficile infection during a hospital outbreak
Bomers, M. K., van Agtmael, M. A., Luik, H., Vandenbroucke‐Grauls, C. M. J. E., & Smulders, Y. M. (2014) · Journal of Infection · doi:10.1016/j.jinf.2014.05.017 · Cited by 31
The Environment Within: Exploring the Role of the Gut Microbiome in Health and Disease
Konkel, L. (2013) · Environmental Health Perspectives · doi:10.1289/ehp.121-a276 · Cited by 38
“The resulting overgrowth of the pathobiont may cause inflammation and bleeding of the lining of the colon.(33) Pathobionts actors that Shape the Gut Com muni ty »»»»» Pharmaceuticals”
BackgroundLaboratory Detection of Clostridium difficile in Piglets in Australia
Knight, D. R., Squire, M. M., & Riley, T. V. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.01225-14 · Cited by 31
“False positives can lead to unnecessary treatment and isolation, and false negatives increase the risk of delay in treatment and cross-infection (44).”
BackgroundRapid, Accurate, and On-Site Detection of C. difficile in Stool Samples
Bomers, M. K., Menke, F. P., Savage, R. S., Vandenbroucke‐Grauls, C. M. J. E., van Agtmael, M. A., Covington, J. A., & Smulders, Y. M. (2015) · The American Journal of Gastroenterology · doi:10.1038/ajg.2015.90 · Cited by 30
Reveles, K. R., Mortensen, E. M., Koeller, J. M., Lawson, K. A., Pugh, M. J., Rumbellow, S. A., Argamany, J. R., & Frei, C. R. (2018) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2088 · Cited by 30
“Clostridium difficile infection (CDI) is the main cause of bacterial infectious diarrhea in nosocomial settings, accounting for 90–100% of antibiotic-associated pseudomembranous colitis cases.(1) Importantly, 14–26% of individuals experience CDI recurrence despite successful treatment of the initial episode.”
BackgroundThe σ B signalling activation pathway in the enteropathogen Clostridioides difficile
Kint, N., Feliciano, C. A., Hamiot, A., Denic, M., Dupuy, B., & Martin‐Verstraete, I. (2019) · Environmental Microbiology · doi:10.1111/1462-2920.14642 · Cited by 26
Gaisawat, M. B., MacPherson, C. W., Tremblay, J., Piano, A., Iskandar, M. M., Tompkins, T. A., & Kubow, S. J. (2019) · Microorganisms · doi:10.3390/microorganisms8010060 · Cited by 35
“CDI usually manifests as diarrhea, and in more severe cases, colonic inflammatory lesions and pseudomembrane formation [2].”
BackgroundCurry, S. R. (2017) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2017.01.007 · Cited by 36
Sheth, P. M., Douchant, K., Uyanwune, Y., Larocque, M., Anantharajah, A., Borgundvaag, E., Dales, L., McCreight, L. J., McNaught, L., Moore, C., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0207138 · Cited by 30
Characterization of a multidrug resistant C. difficile meat isolate
Mooyottu, S., Flock, G. H., Johny, A. K., Upadhyaya, I., Jayarao, B. M., & Venkitanarayanan, K. (2014) · International Journal of Food Microbiology · doi:10.1016/j.ijfoodmicro.2014.10.002 · Cited by 30
“difficile infections (Rupnik et al., 2009; Thitaram et al., 2011).”
BackgroundIdentification and Characterization of Glycoproteins on the Spore Surface of Clostridium difficile
Strong, P. C. R., Fulton, K. M., Aubry, A. J., Foote, S., Twine, S. M., & Logan, S. M. (2014) · Journal of Bacteriology · doi:10.1128/jb.01469-14 · Cited by 30
“difficileassociated diarrhea (CDAD) in the United States indicate as many as 500,000 cases per year with up to 20,000 deaths (1, 3).”
Adult vaccination: Current recommendations and future prospects
Swanson, K. A., Schmitt, H. J., Jansen, K. U., & Anderson, A. S. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.35858 · Cited by 33
“difficile-associated disease (CDAD) an emerging and significant healthcare problem.(35) Similar to S.”
BackgroundGut microbiome-based strategies for host health and disease
Wang, C., Bai, J., Chen, X., Song, J., Zhang, Y., Wang, H., & Suo, H. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2023.2176464 · Cited by 29
“…varies among individuals, which may affect the physiological health, and even increase the probability of individual infection with opportunistic pathogens (Rupnik, Wilcox, and Gerding 2009) and drug-resistant pathogens (Chng et al. 2020) via horizontal transfer of genes (Patangia et al. 2022).”
BackgroundAdvances in the treatment of Clostridium difficile with fidaxomicin: a narrow spectrum antibiotic
Sears, P. S., Ichikawa, Y., Ruíz, N., & Gorbach, S. L. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12135 · Cited by 29
von Müller, L., Mock, M., Halfmann, A., Stahlmann, J., Simon, A., & Herrmann, M. (2015) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2015.08.035 · Cited by 31
Alonso, C. D., & Kamboj, M. (2014) · Current Infectious Disease Reports · doi:10.1007/s11908-014-0414-0 · Cited by 29
García, C. B., Binks, R., Luca, E. D., Dierkes, C., Franci, A., Gallart, E., Niederalt, G., & Wyncoll, D. L. A. (2012) · Intensive and Critical Care Nursing · doi:10.1016/j.iccn.2012.01.005 · Cited by 29
Clostridium difficilehas a single sortase, SrtB, that can be inhibited by small-molecule inhibitors
Donahue, E. H., Dawson, L. F., Valiente, E., Firth-Clark, S., Major, M. R., Littler, E., Perrior, T. R., & Wren, B. W. (2014) · BMC Microbiology · doi:10.1186/s12866-014-0219-1 · Cited by 29
“difficile infection (CDI) [19].”
Romyasamit, C., Thatrimontrichai, A., Aroonkesorn, A., Chanket, W., Ingviya, N., Saengsuwan, P., & Singkhamanan, K. (2020) · Frontiers in Pediatrics · doi:10.3389/fped.2020.572633 · Cited by 31
High Prevalence of Clostridium difficile in Home Gardens in Western Australia
Shivaperumal, N., Chang, B. J., & Riley, T. V. (2020) · Applied and Environmental Microbiology · doi:10.1128/aem.01572-20 · Cited by 31
“antimicrobial-associated diarrhea (1).”
BackgroundDonnelly, M. L., Shrestha, S. D., Ribis, J. W., Kuhn, P., Krasilnikov, M., Feliciano, C. A., & Shen, A. (2022) · mSphere · doi:10.1128/msphere.00132-22 · Cited by 31
Boeriu, A. M., Roman, A., Fofiu, C., & Dobru, D. E. (2022) · Pathogens · doi:10.3390/pathogens11070819 · Cited by 31
“Infection comprises a spectrum of clinical manifestations that range from asymptomatic carriage or mild symptoms to life-threatening conditions (toxic megacolon, colonic perforation) and death [52].”
BackgroundZidarič, V., Kevorkijan, B. K., Orešič, N., Janežič, S., & Rupnik, M. (2011) · Journal of Medical Microbiology · doi:10.1099/jmm.0.030163-0 · Cited by 29
“Clostridium difficile infection (CDI) is one of the most important causes of nosocomial diarrhoea and is also becoming important in the community and in populations with low or no risk factors (Rupnik et al., 2009).”
BackgroundVong, L., Yeung, C. W., Pinnell, L. J., & Sherman, P. M. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000591 · Cited by 31
Clostridium difficile infection in inflammatory bowel disease: challenges in diagnosis and treatment
Tang, Y. M., & Stone, C. D. (2017) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-017-0719-2 · Cited by 33
“This disruption eventually results in decreased transepithelial resistance, fluid accumulation and destruction of the intestinal epithelium [4].”
Background
Metadata
- Authors
- Rupnik, M., Wilcox, M. H., & Gerding, D. N.
- Affiliations
- University of Maribor (SI)
- Leeds General Infirmary (GB)
- Loyola University Chicago (US)
- Venue
- Nature Reviews Microbiology
- Published
- 2009-07
- Volume
- 7
- Issue
- 7
- Pages
- 526-536
- ISSN
- 1740-1526 (ISSN-L)
- 1740-1534
- OpenAlex
- W1968953113
- Cited by
- 1,380
- References
- 124
- Citations by year
- 2026: 18 · 2025: 36 · 2024: 49 · 2023: 59 · 2022: 74 · 2021: 72 · 2020: 88 · 2019: 78 · 2018: 109 · 2017: 104 · 2016: 107 · 2015: 107 · 2014: 133 · 2013: 141 · 2012: 93
- FWCI
- 8.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Microbiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Health Sciences › Medicine › Infectious Diseases › Infection Control in Healthcare
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Keywords
- Clostridium difficile infection, nosocomial infections, virulence factors, epidemiology, pathogenesis, community-acquired infections, food-producing animals, antibiotic-associated diarrhea, clinical outcomes, infection prevention and treatment
- MeSH terms
- Animals, Anti-Bacterial Agents, Enterocolitis, Pseudomembranous, Humans, Models, Theoretical, Clostridioides difficile, Virulence Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.